GT Biopharma, Inc.GTBPNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank64
3Y CAGR-26.7%
5Y CAGR+48.2%
Year-over-Year Change
Research and development spending
3Y CAGR
-26.7%/yr
vs -0.7%/yr prior
5Y CAGR
+48.2%/yr
Recent deceleration
Acceleration
-26.0pp
Decelerating
Percentile
P64
Within normal range
vs 5Y Ago
7.2x
Strong expansion
Streak
4 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $3.47M | -40.1% |
| 2024 | $5.80M | -10.3% |
| 2023 | $6.47M | -26.6% |
| 2022 | $8.81M | -8.1% |
| 2021 | $9.59M | +1877.5% |
| 2020 | $485000.00 | -70.9% |
| 2019 | $1.67M | -81.6% |
| 2018 | $9.07M | +749.0% |
| 2017 | $1.07M | +9.5% |
| 2016 | $975000.00 | - |